A significant decrease in serum IL-6 and IL-8 levels between pre- and post-treatment samples was observed in newly presenting HNSCC patients after initial treatment (62), which suggests that decreasing levels of IL-6 and IL-8 may function as good prognostic factors under pembrolizumab treatment as well. The gene discussed is IL6; the disease is head and neck squamous cell carcinoma.